Transcriptional Profiling of GBM Invasion Genes Identifies Effective Inhibitors of the LIM Kinase-Cofilin Pathway
Overview
Authors
Affiliations
Malignant gliomas are highly proliferative and invasive neoplasms where total surgical resection is often impossible and effective local radiation therapy difficult. Consequently, there is a need to develop a greater understanding of the molecular events driving invasion and to identify novel treatment targets. Using microarray analysis comparing normal brain samples and mesenchymal glioblastoma multiforme (GBM), we identified over 140 significant genes involved in cell migration and invasion. The cofilin (CFL) pathway, which disassembles actin filaments, was highly up-regulated compared to normal brain. Up-regulation of LIM domain kinase 1 and 2 (LIMK1/2), that phosphorylates and inactivates cofilin, was confirmed in an additional independent data set comparing normal brain to GBM. We identified and utilized two small molecule inhibitors BMS-5 and Cucurbitacin I directed against the cofilin regulating kinases, LIMK1 and LIMK2, to target this pathway. Significant decreases in cell viability were observed in glioma cells treated with BMS-5 and Cucurbitacin I, while no cytotoxic effects were seen in normal astrocytes that lack LIMK. BMS-5 and Cucurbitacin I promoted increased adhesion in GBM cells, and decreased migration and invasion. Collectively, these data suggest that use of LIMK inhibitors may provide a novel way to target the invasive machinery in GBM.
Biphasic regulation of epigenetic state by matrix stiffness during cell reprogramming.
Song Y, Soto J, Wong S, Wu Y, Hoffman T, Akhtar N Sci Adv. 2024; 10(7):eadk0639.
PMID: 38354231 PMC: 10866547. DOI: 10.1126/sciadv.adk0639.
Villalonga E, Mosrin C, Normand T, Girardin C, Serrano A, Zunar B Cells. 2023; 12(5).
PMID: 36899941 PMC: 10000741. DOI: 10.3390/cells12050805.
Cofilin Acts as a Booster for Progression of Malignant Tumors Represented by Glioma.
Lv S, Chen Z, Mi H, Yu X Cancer Manag Res. 2022; 14:3245-3269.
PMID: 36452435 PMC: 9703913. DOI: 10.2147/CMAR.S389825.
Patel A, Rasheed A, Reilly I, Pareek Z, Hansen M, Haque Z Pharmaceuticals (Basel). 2022; 15(11).
PMID: 36355554 PMC: 9698530. DOI: 10.3390/ph15111380.
The microtubule cytoskeleton: An old validated target for novel therapeutic drugs.
Lafanechere L Front Pharmacol. 2022; 13:969183.
PMID: 36188585 PMC: 9521402. DOI: 10.3389/fphar.2022.969183.